MétaCan
Menu
Back to cohort
Record W4416787220 · doi:10.1186/s12961-025-01421-w

Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society

2025· article· en· W4416787220 on OpenAlexafffund
Anna Wong, Gul Saeed, Sarah Garner, Jillian Clare Köhler

Bibliographic record

VenueHealth Research Policy and Systems · 2025
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsToronto Public HealthPublic Health OntarioUniversity of Toronto
FundersUniversity of TorontoWorld Health Organization
KeywordsCivil societyCorporate social responsibilityGovernment (linguistics)Public healthHealth services researchSocial policyCorporate governance

Abstract

fetched live from OpenAlex

BACKGROUND: Corporate social responsibility (CSR) activity in the pharmaceutical industry is frequently directed towards improving patient access to medicines amongst low-income populations. This research reports on findings from a mixed literature and key informant study of pharmaceutical sector CSR activity and its applicability in the high-cost novel therapeutics space. METHODS: Academic and grey literature documents were extracted from online databases in a rapid literature review, focusing on four key areas of interest: (i) CSR or benefit company activity, (ii) the pharmaceutical industry, (iii) the development and sale of high-cost novel medicines and (iv) the role of government and civil society in this space. Ten semistructured interviews amongst key informants, including medical activists, pharmaceutical industry representatives, patient advocates, employees at nongovernmental organizations (NGOs), consultants for international organizations and academic researchers were also conducted related to these topics. RESULTS: We find that CSR strategies vary depending on partner identity and country ability to pay. Differential pricing schemes and flexible patent approaches tend to be pursued unilaterally by companies, whereas companies frequently partner with local private sector, government, nongovernmental organizations and academic actors when implementing patient support programs, medicines donations, medicines delivery programs and rare and neglected disease research and development (R&D) initiatives. Patient support programs are more prevalent in high-income countries with minimal state-subsidized healthcare, whilst differential and tiered pricing strategies are more frequently pursued in lower-income countries. CONCLUSIONS: Pharmaceutical CSR strategies may benefit from greater coordination with government and civil society actors. Opportunities for government and civil society actors to take an active role in better aligning CSR activity with patient needs and universal health coverage include promoting greater adoption of alternative corporate structures and providing active external recognition of successful CSR initiatives through reputational and funding awards.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.133
metaresearch head score (Gemma)0.014
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Science and technology studies
Consensus categoriesMetaresearch
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.695
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.1330.014
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0030.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.857
GPT teacher head0.623
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designTheoretical or conceptual
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueHealth Research Policy and SystemsSame topicHealth Systems, Economic Evaluations, Quality of LifeFrench-language works237,207